Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387660 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
A Phase 2 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00387660 is a Phase 2 study that has completed, run by University of California, Davis. The registered enrollment target is 80 participants.
The verdict
NCT00387660, a Phase 2 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with carboplatin works in treating patients with metastatic or recurrent small cell lung cancer.
Interventions
- DRUG carboplatin
- DRUG irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2001-10 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387660
The ClinicalTrials.gov registry entry for NCT00387660 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.
NCT00387660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387660 about?
NCT00387660 is a clinical study titled "Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as irinotecan and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II ...
What is the current status of trial NCT00387660?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2001-10. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00387660?
The interventions under investigation include: carboplatin (DRUG), irinotecan (DRUG).
Who is sponsoring clinical trial NCT00387660?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.